Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase I/II clinical study, to assess the safety,
tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also
known as EOS-448 or GSK4428859A), alone or in combination with iberdomide with and without
dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM).